A promising bioconjugate vaccine against hypervirulent


Journal

Proceedings of the National Academy of Sciences of the United States of America
ISSN: 1091-6490
Titre abrégé: Proc Natl Acad Sci U S A
Pays: United States
ID NLM: 7505876

Informations de publication

Date de publication:
10 09 2019
Historique:
pubmed: 29 8 2019
medline: 9 4 2020
entrez: 29 8 2019
Statut: ppublish

Résumé

Hypervirulent

Identifiants

pubmed: 31455739
pii: 1907833116
doi: 10.1073/pnas.1907833116
pmc: PMC6744904
doi:

Substances chimiques

Bacterial Vaccines 0
Carrier Proteins 0
Lipopolysaccharides 0
Vaccines, Conjugate 0
Virulence Factors 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

18655-18663

Subventions

Organisme : NIAID NIH HHS
ID : K08 AI127714
Pays : United States
Organisme : NIAID NIH HHS
ID : R41 AI136233
Pays : United States

Informations de copyright

Copyright © 2019 the Author(s). Published by PNAS.

Déclaration de conflit d'intérêts

Conflict of interest statement: M.F.F. and C.M.H. have a financial stake in VaxNewMo, a for-profit entity developing bioconjugate vaccines against Streptococcus pneumoniae and Klebsiella pneumoniae using patented technology derived from the data presented in this and other published manuscripts.

Références

Infect Immun. 1999 Sep;67(9):4935-8
pubmed: 10456954
J Biol Chem. 1999 Dec 3;274(49):35129-38
pubmed: 10574995
J Exp Med. 2004 Mar 1;199(5):697-705
pubmed: 14993253
Proc Natl Acad Sci U S A. 2005 Feb 22;102(8):3016-21
pubmed: 15703289
Mol Microbiol. 2005 Mar;55(6):1695-703
pubmed: 15752194
Carbohydr Res. 2005 Sep 26;340(13):2212-7
pubmed: 16054607
J Infect. 2007 Jun;54(6):578-83
pubmed: 17175028
J Bacteriol. 2007 Nov;189(22):8088-98
pubmed: 17890310
Emerg Infect Dis. 2007 Jul;13(7):986-93
pubmed: 18214169
Diagn Microbiol Infect Dis. 2008 Sep;62(1):1-6
pubmed: 18486404
Arch Intern Med. 1991 Aug;151(8):1557-9
pubmed: 1872659
J Bacteriol. 2009 Jul;191(14):4492-501
pubmed: 19447910
Vaccine. 2009 Oct 30;27(46):6468-70
pubmed: 19555714
Infect Immun. 1991 Jun;59(6):2043-50
pubmed: 2037364
J Bacteriol. 2010 Jun;192(12):3144-58
pubmed: 20382770
J Biol Chem. 2011 Jun 17;286(24):21041-51
pubmed: 21478151
Microbiology. 2011 Dec;157(Pt 12):3446-57
pubmed: 21964731
Clin Infect Dis. 2012 Oct;55(7):930-9
pubmed: 22715175
Virulence. 2013 Feb 15;4(2):107-18
pubmed: 23302790
PLoS One. 2013;8(2):e56847
pubmed: 23457627
N Engl J Med. 2014 Mar 27;370(13):1198-208
pubmed: 24670166
BMC Biol. 2014 May 29;12:41
pubmed: 24885329
Nat Rev Immunol. 2014 Jul;14(7):505-14
pubmed: 24925139
PLoS One. 2014 Sep 09;9(9):e107394
pubmed: 25203254
Mol Microbiol. 2015 Jun;96(5):1023-41
pubmed: 25727908
Clin Microbiol Rev. 2015 Jul;28(3):871-99
pubmed: 26085553
Sci Rep. 2015 Oct 23;5:15573
pubmed: 26493302
Antimicrob Agents Chemother. 2015 Nov 16;60(1):709-11
pubmed: 26574010
Sci Rep. 2016 Apr 22;6:24931
pubmed: 27103188
MBio. 2016 Apr 26;7(2):e00443-16
pubmed: 27118590
Lancet Infect Dis. 2016 Sep;16(9):e190-e195
pubmed: 27402393
Antimicrob Agents Chemother. 2016 Sep 23;60(10):6115-20
pubmed: 27480857
Clin Vaccine Immunol. 2016 Dec 5;23(12):908-917
pubmed: 27581434
Clin Vaccine Immunol. 2017 Jan 5;24(1):
pubmed: 27795303
Lancet Infect Dis. 2017 May;17(5):528-537
pubmed: 28238601
Lancet Infect Dis. 2018 Jan;18(1):37-46
pubmed: 28864030
J Med Microbiol. 2018 Jan;67(1):118-128
pubmed: 29205138
Front Cell Infect Microbiol. 2017 Nov 21;7:483
pubmed: 29209595
Antimicrob Agents Chemother. 2018 Jun 26;62(7):
pubmed: 29712659
PLoS One. 2018 Sep 6;13(9):e0203143
pubmed: 30188914
J Antimicrob Chemother. 2018 Dec 1;73(12):3317-3321
pubmed: 30239821
Chem Soc Rev. 2018 Dec 10;47(24):9015-9025
pubmed: 30277489
Expert Rev Anti Infect Ther. 2019 Feb;17(2):71-73
pubmed: 30501374
Antimicrob Agents Chemother. 2019 Feb 26;63(3):null
pubmed: 30602516
Ann Clin Microbiol Antimicrob. 2019 Jan 21;18(1):4
pubmed: 30665418
Nat Commun. 2019 Feb 21;10(1):891
pubmed: 30792408
Glycobiology. 2019 Jul 1;29(7):519-529
pubmed: 30989179
NPJ Vaccines. 2019 May 1;4:16
pubmed: 31069118
J Exp Med. 1988 Jul 1;168(1):127-42
pubmed: 3260935
J Med Microbiol. 1988 May;26(1):29-35
pubmed: 3286873
Arch Intern Med. 1986 Oct;146(10):1913-6
pubmed: 3532983
Vaccine. 1994 Nov;12(14):1288-94
pubmed: 7856293
Carbohydr Res. 1976 Aug;50(1):115-20
pubmed: 975115

Auteurs

Mario F Feldman (MF)

Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO 63110.
VaxNewMo, St. Louis, MO 63108.

Anne E Mayer Bridwell (AE)

Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO 63110.

Nichollas E Scott (NE)

Department of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, University of Melbourne, Parkville, VIC 3010, Australia.

Evgeny Vinogradov (E)

Human Health Therapeutics, National Research Council Canada, Ottawa, ON K1A 0R6, Canada.

Samuel R McKee (SR)

Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO 63110.

Sthefany M Chavez (SM)

Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO 63110.

Joy Twentyman (J)

Division of Pediatric Infectious Diseases, Department of Pediatrics, Washington University School of Medicine, St. Louis, MO 63110.

Christina L Stallings (CL)

Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO 63110.

David A Rosen (DA)

Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO 63110.
Division of Pediatric Infectious Diseases, Department of Pediatrics, Washington University School of Medicine, St. Louis, MO 63110.

Christian M Harding (CM)

VaxNewMo, St. Louis, MO 63108; christian.harding@vaxnewmo.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH